Streetbeat News

Earnings

QS

QuantumScape shares are trading lower after the company reported worse-than-expected EPS results.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 8:30 pm

WCN

Waste Connections (NYSE:WCN) reported Q2 2024 adjusted EPS of $1.24, beating the analyst estimate of $1.17. The company also reported sales of $2.248 billion, surpassing the $2.220 billion estimate. This represents an 11.23% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 8:30 pm

PI

Impinj shares are trading higher after the company reported better-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 8:29 pm

F

Ford Motor Company (NYSE:F) reported Q2 earnings with a revenue beat but an EPS miss. Revenue was $47.8 billion, up 6% YoY, beating the $44 billion estimate. EPS was 47 cents, missing the 68 cents estimate. Ford Blue and Ford Pro segments showed growth, while Ford Model e saw a 37% decline in revenue. The company reiterated its full-year EBIT guidance and plans to increase production capacity for Super Duty trucks.

Portfolio Pulse from Chris Katje

July 24, 2024 | 8:29 pm

LVS

Las Vegas Sands shares are trading lower following a Q2 earnings miss.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 8:29 pm

RHI

Robert Half shares are trading lower after the company reported worse-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 8:28 pm

UHS

Universal Health Services shares are trading higher after the company reported a Q2 earnings beat.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 8:28 pm

PEB

Pebblebrook Hotel (NYSE:PEB) reported Q2 2024 earnings of $0.69 per share, beating the analyst estimate of $0.61 by 13.11%. Sales were $397.110M, slightly above the $396.421M estimate. Both earnings and sales showed year-over-year growth.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 8:28 pm

TYL

Tyler Technologies has provided its financial guidance for FY24, expecting revenues between $2.12 billion and $2.15 billion, slightly below the $2.13 billion estimate. GAAP EPS is projected to be between $5.76 and $5.96, while non-GAAP EPS is expected to range from $9.25 to $9.45. The company also anticipates a free cash flow margin of 18% to 20%, R&D expenses of $122 million to $125 million, and capital expenditures of $50 million to $52 million.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 8:28 pm

VKTX

Viking Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 8:28 pm